Alk, officially known as Alk Abello A/S, is a leading player in the biopharmaceutical industry, headquartered in Denmark (DK). Founded in 1923, the company has established itself as a pioneer in allergy immunotherapy, focusing on innovative treatments for allergic conditions. With a strong presence in Europe and North America, Alk is dedicated to improving the quality of life for allergy sufferers through its advanced products. The company’s core offerings include sublingual and injectable immunotherapy solutions, which are distinguished by their efficacy and patient-friendly administration methods. Alk's commitment to research and development has positioned it as a market leader, achieving significant milestones such as the introduction of the first sublingual tablet for grass pollen allergy. With a robust portfolio and a focus on patient-centric solutions, Alk continues to drive advancements in allergy treatment.
How does Alk's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Alk's score of 35 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, ALK-Abelló A/S reported total greenhouse gas emissions of approximately 69,555,000 kg CO2e. This figure includes Scope 1 emissions of about 5,128,000 kg CO2e, which comprise mobile combustion (1,454,000 kg CO2e) and fugitive emissions (501,000 kg CO2e). Scope 2 emissions totalled around 5,917,000 kg CO2e, with a market-based approach accounting for 360,000 kg CO2e. The company also disclosed Scope 3 emissions of approximately 64,067,000 kg CO2e, primarily from purchased goods and services (41,175,000 kg CO2e) and employee commuting (6,153,000 kg CO2e). ALK has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 GHG emissions by 42% by 2030, using 2022 as the baseline year. This target is aligned with the Science Based Targets initiative (SBTi) and includes biogenic emissions and removals from bioenergy feedstocks. Additionally, ALK plans for 80% of its suppliers, covering various categories such as purchased goods and services, to establish science-based targets by 2028. The company achieved a significant reduction of 41% in Scope 1 and 2 emissions from a 2019 baseline by 2022, demonstrating its commitment to sustainability and climate action. ALK's emissions data and targets are sourced directly from its own disclosures, ensuring transparency and accountability in its environmental impact efforts.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 5,479,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 3,003,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 |
| Scope 3 | 4,244,000 | 000,000 | 000,000 | 00,000,000 | 00,000,000 |
Alk's Scope 3 emissions, which decreased by 9% last year and increased significantly since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 64% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Alk has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
